Conferences
ASCO GU 2022: Bladder-Sparing Trimodality Therapy: Toxicity and Functional Outcomes in the Era of Novel Therapeutics
February 25, 2022
ASCO GU 2022: ABLE: Phase 2, Single-Arm, Two-Stage Study of Nab-Paclitaxel with Anti-PD1/PDL1 in Advanced Urothelial Cancer
February 25, 2022
ASCO GU 2022: Post Hoc Analysis of the Efficacy of Pembrolizumab Retreatment After Progression of Advanced Urothelial Carcinoma in KEYNOTE-045 and KEYNOTE-052
February 24, 2022
ASCO GU 2022: PD-L1 Expression and BCG Response in Nonmuscle Invasive Bladder Cancer (NMIBC)
February 24, 2022
ASCO GU 2022: Study RC48-C014: Preliminary Results of RC48-ADC Combined with Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
February 24, 2022
ASCO GU 2022: Treatment Outcomes for mCRPC Following Progression on Upfront ADT with Androgen Receptor Pathway Inhibitors for mCSPC
February 24, 2022
ASCO GU 2022: The TRAP Trial: Targeting Resistant Prostate Cancer, with or without DNA Repair Defects, Using the Combination of Ceralasertib and Olaparib
February 24, 2022